Mesoblast LtdNASDAQ:MESO
- LAST PRICE5.2100
- TODAY'S CHANGE (%)0.1000 (1.9569%)
- Bid / Lots4.5000/ 11
- Ask / Lots5.4000/ 7
- Open / Previous Close5.0600 / 5.1100
- Day Range
- 52 Week Range
- Volume226,392
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MESO |
|---|---|---|
| 09:32 ET | 1115 | 5.06 |
| 09:34 ET | 333 | 5.08 |
| 09:38 ET | 994 | 5.1355 |
| 09:39 ET | 4634 | 5.165 |
| 09:41 ET | 1100 | 5.2 |
| 09:43 ET | 502 | 5.225 |
| 09:45 ET | 3450 | 5.3 |
| 09:48 ET | 1230 | 5.2501 |
| 09:50 ET | 4862 | 5.3136 |
| 09:52 ET | 1879 | 5.295 |
| 09:54 ET | 1348 | 5.26 |
| 09:56 ET | 1600 | 5.282 |
| 09:57 ET | 1300 | 5.282 |
| 09:59 ET | 1225 | 5.305 |
| 10:01 ET | 2300 | 5.3 |
| 10:03 ET | 1500 | 5.275 |
| 10:06 ET | 1808 | 5.252 |
| 10:08 ET | 500 | 5.275 |
| 10:10 ET | 200 | 5.26 |
| 10:12 ET | 1757 | 5.26 |
| 10:14 ET | 500 | 5.28 |
| 10:15 ET | 200 | 5.256 |
| 10:17 ET | 444 | 5.28 |
| 10:19 ET | 3000 | 5.31 |
| 10:21 ET | 2687 | 5.312 |
| 10:24 ET | 1400 | 5.29 |
| 10:26 ET | 2025 | 5.3 |
| 10:28 ET | 1120 | 5.29 |
| 10:30 ET | 1157 | 5.252 |
| 10:32 ET | 400 | 5.26 |
| 10:33 ET | 425 | 5.26 |
| 10:35 ET | 300 | 5.275 |
| 10:37 ET | 440 | 5.28 |
| 10:39 ET | 4735 | 5.24 |
| 10:42 ET | 500 | 5.211 |
| 10:44 ET | 3093 | 5.19 |
| 10:46 ET | 600 | 5.182 |
| 10:48 ET | 1296 | 5.148 |
| 10:50 ET | 1737 | 5.14 |
| 10:51 ET | 500 | 5.14 |
| 10:53 ET | 2364 | 5.15 |
| 10:55 ET | 2469 | 5.15 |
| 10:57 ET | 650 | 5.15 |
| 11:00 ET | 652 | 5.16 |
| 11:02 ET | 100 | 5.16 |
| 11:04 ET | 300 | 5.15 |
| 11:06 ET | 285 | 5.155 |
| 11:08 ET | 1845 | 5.18 |
| 11:09 ET | 2024 | 5.2 |
| 11:11 ET | 800 | 5.2 |
| 11:13 ET | 100 | 5.2 |
| 11:15 ET | 100 | 5.2 |
| 11:18 ET | 200 | 5.2 |
| 11:20 ET | 360 | 5.185 |
| 11:24 ET | 100 | 5.195 |
| 11:26 ET | 100 | 5.2 |
| 11:27 ET | 200 | 5.2 |
| 11:29 ET | 267 | 5.2 |
| 11:31 ET | 2900 | 5.2 |
| 11:33 ET | 300 | 5.1705 |
| 11:36 ET | 1746 | 5.2 |
| 11:38 ET | 700 | 5.2 |
| 11:40 ET | 845 | 5.2 |
| 11:42 ET | 254 | 5.19 |
| 11:44 ET | 100 | 5.2 |
| 11:45 ET | 575 | 5.19 |
| 11:47 ET | 100 | 5.2 |
| 11:49 ET | 100 | 5.195 |
| 11:54 ET | 834 | 5.17 |
| 11:56 ET | 200 | 5.17 |
| 12:02 ET | 100 | 5.18 |
| 12:03 ET | 100 | 5.18 |
| 12:05 ET | 257 | 5.17 |
| 12:07 ET | 100 | 5.1625 |
| 12:09 ET | 2380 | 5.19 |
| 12:12 ET | 140 | 5.198 |
| 12:14 ET | 200 | 5.2 |
| 12:16 ET | 100 | 5.1925 |
| 12:20 ET | 400 | 5.1701 |
| 12:21 ET | 100 | 5.1925 |
| 12:23 ET | 2059 | 5.155 |
| 12:27 ET | 399 | 5.1 |
| 12:30 ET | 339 | 5.1 |
| 12:34 ET | 100 | 5.12 |
| 12:50 ET | 2400 | 5.1 |
| 12:52 ET | 100 | 5.11 |
| 12:57 ET | 100 | 5.11 |
| 12:59 ET | 100 | 5.13 |
| 01:03 ET | 100 | 5.13 |
| 01:15 ET | 150 | 5.11 |
| 01:19 ET | 1286 | 5.16 |
| 01:21 ET | 1150 | 5.16 |
| 01:24 ET | 100 | 5.17 |
| 01:26 ET | 157 | 5.18 |
| 01:28 ET | 200 | 5.19 |
| 01:30 ET | 259 | 5.2 |
| 01:32 ET | 501 | 5.22 |
| 01:35 ET | 309 | 5.23 |
| 01:37 ET | 395 | 5.23 |
| 01:39 ET | 200 | 5.23 |
| 01:42 ET | 250 | 5.2241 |
| 01:46 ET | 200 | 5.24 |
| 01:48 ET | 300 | 5.24 |
| 01:53 ET | 575 | 5.23 |
| 01:55 ET | 290 | 5.23 |
| 01:57 ET | 100 | 5.24 |
| 02:00 ET | 425 | 5.23 |
| 02:04 ET | 5915 | 5.181 |
| 02:06 ET | 100 | 5.18 |
| 02:09 ET | 100 | 5.18 |
| 02:11 ET | 100 | 5.18 |
| 02:13 ET | 100 | 5.2025 |
| 02:15 ET | 400 | 5.1869 |
| 02:18 ET | 200 | 5.21 |
| 02:20 ET | 100 | 5.2025 |
| 02:22 ET | 200 | 5.2025 |
| 02:24 ET | 400 | 5.195 |
| 02:26 ET | 1155 | 5.2 |
| 02:27 ET | 320 | 5.194 |
| 02:31 ET | 200 | 5.21 |
| 02:33 ET | 100 | 5.21 |
| 02:38 ET | 200 | 5.21 |
| 02:42 ET | 400 | 5.21 |
| 02:44 ET | 300 | 5.22 |
| 02:45 ET | 1445 | 5.195 |
| 02:47 ET | 3400 | 5.17 |
| 02:49 ET | 407 | 5.18 |
| 02:56 ET | 250 | 5.18 |
| 02:58 ET | 100 | 5.18 |
| 03:00 ET | 100 | 5.18 |
| 03:02 ET | 200 | 5.175 |
| 03:03 ET | 200 | 5.18 |
| 03:05 ET | 100 | 5.18 |
| 03:07 ET | 18268 | 5.13 |
| 03:09 ET | 20557 | 5.093 |
| 03:16 ET | 1064 | 5.13 |
| 03:18 ET | 200 | 5.14 |
| 03:20 ET | 400 | 5.15 |
| 03:21 ET | 1300 | 5.15 |
| 03:23 ET | 5781 | 5.18 |
| 03:25 ET | 1507 | 5.19 |
| 03:27 ET | 200 | 5.19 |
| 03:30 ET | 1300 | 5.17 |
| 03:34 ET | 500 | 5.15 |
| 03:36 ET | 534 | 5.155 |
| 03:38 ET | 706 | 5.165 |
| 03:39 ET | 100 | 5.165 |
| 03:41 ET | 592 | 5.165 |
| 03:43 ET | 1614 | 5.15 |
| 03:48 ET | 1510 | 5.17 |
| 03:50 ET | 257 | 5.18 |
| 03:54 ET | 757 | 5.18 |
| 03:56 ET | 764 | 5.18 |
| 03:57 ET | 4645 | 5.21 |
| 03:59 ET | 3192 | 5.21 |
Apr 8, 2024
DJ Mesoblast Could Now Generate Meaningful FY 2025 Revenue -- Market Talk, from 12:49AM ET on Monday Apr 08, 2024 by Dow Jones
12:49AM ET on Monday Apr 08, 2024 by Dow Jones
Apr 7, 2024
*DJ Mesoblast Price Target Raised to A$1.40/Share From A$0.58 by Bell Potter, from 6:17PM ET on Sunday Apr 07, 2024 by Dow Jones
6:17PM ET on Sunday Apr 07, 2024 by Dow Jones
Mar 26, 2024
DJ Mesoblast Up Over 59%, on Pace for Largest Percent Increase Since April 2020 -- Data Talk, from 12:14PM ET on Tuesday Mar 26, 2024 by Dow Jones
12:14PM ET on Tuesday Mar 26, 2024 by Dow JonesDJ Mesoblast Shares Jump After FDA Nod for Submission of Remestemcel-L Application, from 8:14AM ET on Tuesday Mar 26, 2024 by Dow Jones
8:14AM ET on Tuesday Mar 26, 2024 by Dow Jones*DJ Mesoblast Price Target Raised 14% to A$0.80/Share by Jefferies, from 1:35AM ET on Tuesday Mar 26, 2024 by Dow Jones
1:35AM ET on Tuesday Mar 26, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Mesoblast Ltd | 568.8M | -3.6x | --- |
Absci Corp | 560.5M | -4.0x | --- |
Verve Therapeutics Inc | 556.9M | -2.1x | --- |
Stoke Therapeutics Inc | 599.7M | -5.1x | --- |
Compass Pathways PLC | 575.4M | -3.5x | --- |
Astria Therapeutics Inc | 578.7M | -4.2x | --- |
Company Information
Mesoblast Limited is an Australia-based is developing a range of late-stage product candidates derived from its proprietary mesenchymal lineage cell therapy technology platforms. The Company’s Remestemcel-L is mesenchymal lineage stromal cell product platform and is in late-stage development for treatment of systemic inflammatory diseases, including Pediatric steroid refractory acute Graft versus Host Disease (SR-aGVHD), acute respiratory distress syndrome (ARDS) and Biologic refractory inflammatory bowel disease. Its Rexlemestrocel-L is mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of advanced chronic heart failure (CHF) and chronic low back pain (CLBP) due to degenerative disc disease. Two products are commercialized in Japan and Europe by the Company’s licensees, and it has a commercial partnership in Europe and China for certain Phase III assets.
Contact Information
- Headquarters
- L 38 55 Collins StMELBOURNE, VIC, Australia 3000
- Phone
- ---
- Fax
- ---
Executives
- Non-Executive Independent Chairman of the Board
- Jane Bell
- Chief Executive Officer, Executive Director
- Silviu Itescu
- Non-Executive Independent Vice Chairman of the Board
- William Burns
- Interim Chief Financial Officer
- Andrew Chaponnel
- Chief Operating Officer
- Dagmar Rosa-Bjorkeson
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $568.8M |
|---|---|
Revenue (TTM) | $7.5M |
Shares Outstanding | 114.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 3.54 |
EPS | $-1.44 |
Book Value | $12.34 |
P/E Ratio | -3.6x |
Price/Sales (TTM) | 76.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -735.47% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
